Sugi Predict

Sugi Predict / Targets / POLE3

POLE3

DNA polymerase epsilon subunit 3 · Q9NRF9 · POLE3 on Sugi Atlas →

24 patent compounds predicted against POLE3, 23 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21643657 SCHEMBL21643657 1.00 1/20
SCHEMBL21673021 SCHEMBL21673021 1.00 1/20
SCHEMBL21673017 SCHEMBL21673017 0.76 1/20
SCHEMBL21643639 SCHEMBL21643639 0.71 1/20
SCHEMBL21673012 SCHEMBL21673012 0.71 1/20
SCHEMBL21673031 SCHEMBL21673031 0.71 1/20
SCHEMBL21643632 SCHEMBL21643632 0.64 1/20
SCHEMBL21673013 SCHEMBL21673013 0.64 1/20
SCHEMBL21643634 SCHEMBL21643634 0.63 1/20
SCHEMBL21673022 SCHEMBL21673022 0.63 1/20
SCHEMBL21673037 SCHEMBL21673037 0.57 1/20
SCHEMBL21673016 SCHEMBL21673016 0.56 1/20
SCHEMBL21706132 SCHEMBL21706132 0.56 1/20
SCHEMBL21643659 SCHEMBL21643659 0.54 1/20
SCHEMBL21673026 SCHEMBL21673026 0.54 1/20
SCHEMBL21673024 SCHEMBL21673024 0.53 1/20
SCHEMBL21673011 SCHEMBL21673011 0.50 1/20
SCHEMBL21673014 SCHEMBL21673014 0.47 1/20
SCHEMBL21706191 SCHEMBL21706191 0.46 1/20
SCHEMBL21673023 SCHEMBL21673023 0.43 1/20

Clinical trials — most relevant to POLE3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PHASE2/PHASE3RECRUITING
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2COMPLETED
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors PHASE2RECRUITING
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability PHASE2ACTIVE_NOT_RECRUITING
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations PHASE2NOT_YET_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor PHASE2UNKNOWN
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study PHASE1WITHDRAWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Tabectedin to Treat Children and Adolescents With Cancer PHASE1COMPLETED
Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study PHASE1COMPLETED
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification nanRECRUITING
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer nanNOT_YET_RECRUITING
Cohort of Tumors With POLE/D1 Mutation nanRECRUITING
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals nanRECRUITING
PErsonalized TReatment for Endometrial Carcinoma nanRECRUITING
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare) nanACTIVE_NOT_RECRUITING
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation nanUNKNOWN
Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms nanUNKNOWN
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer nanCOMPLETED
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care nanCOMPLETED
Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation nanNOT_YET_RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Men at High Genetic Risk for Prostate Cancer nanRECRUITING
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study nanUNKNOWN
Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a POLE3 binder may also engage these)

ProteinNameSimilarity
Q5R4W3 — 1.000 Q5R4W3 →
Q3SZN5 — 1.000 Q3SZN5 →
Q642A5 — 1.000 Q642A5 →
Q9JKP7 — 1.000 Q9JKP7 →
Q9V444 — 0.988 Q9V444 →
Q75JQ9 — 0.987 Q75JQ9 →
Q6CHS6 — 0.986 Q6CHS6 →
Q6CJD7 — 0.986 Q6CJD7 →
Q9W256 — 0.984 Q9W256 →
P13434 — 0.983 P13434 →
P11747 — 0.982 P11747 →
Q04603 — 0.982 Q04603 →
Q10315 — 0.981 Q10315 →
Q6FXD0 — 0.981 Q6FXD0 →
Q9JKP8 — 0.981 Q9JKP8 →
P36611 — 0.981 P36611 →
Q6BIP4 — 0.980 Q6BIP4 →
Q9SLG0 — 0.980 Q9SLG0 →
O04027 — 0.980 O04027 →
Q6C6M5 — 0.979 Q6C6M5 →
O23310 — 0.979 O23310 →
Q07205 — 0.979 Q07205 →
A5DGN9 — 0.978 A5DGN9 →
Q9NRG0 — 0.978 Q9NRG0 →
Q9V452 — 0.978 Q9V452 →
Q59SU5 — 0.977 Q59SU5 →
Q55DJ5 — 0.977 Q55DJ5 →
Q6CMV8 — 0.977 Q6CMV8 →
A6ZPY2 — 0.977 A6ZPY2 →
Q6NRI8 — 0.977 Q6NRI8 →